Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky. Merger with Tourmaline Bio (TRML) on Oct. 19. 2023. TRML is the surviving entity. Show more
Location: | Website: talaristx.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$16.28
Open
$16.41
Volume
210,434
Day Range
$16.38 - $18.15
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
11.91%
Institutional Own.
77.67%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
FCR001 Details Renal Transplantation | Failed Discontinued |